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CLINICAL REPORT
Acquisition and Clearance of Perianal Human Papillomavirus
Infection in Relation to HIV-positivity in Men Who Have Sex with
Men in the Netherlands
Eric M. VAN DER SNOEK1, Hubert G. M. NIESTERS2, Gerard J. J. VAN DOORNUM2, Paul G. H. MULDER3, Albert
D. M. E. OSTERHAUS2 and Willem I. VAN DER MEIJDEN1
Departments of 1Dermatology and Venereology, 2Virology and 3Institute of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, The Netherlands
This study was performed to establish the prevalence of
perianal human papillomavirus (HPV) infection in relation
to HIV-positivity in a group of men who have sex with men
(MSM), and to correlate follow-up data with regard to
acquisition and clearance of HPV infection. Data with
regard to HPV prevalence and HIV serostatus during two
visits were compared. At both visits participants underwent
a routine venereological examination and swabs were taken
from the perianal region for HPV DNA testing. During
both visits HPV types 16, 18, 31, 33 and 52 were
significantly more often detected in HIV-positive indivi-
duals. Persistence of HPV type 31 at the perianal region
was significantly more often seen in HIV-positive MSM
(p50.036) while the incidence of type 16 may be associated
with HIV positivity (p50.059). In HIV-positive MSM
significantly more high-risk HPV types were detected at the
perianal region. Key words: homosexual; persistence;
perianal infection.
(Accepted January 14, 2005.)
Acta Derm Venereol 2005; 85: 437–443.
Eric van der Snoek, Department of Dermatology and
Venereology, Erasmus MC, Dr. Molewaterplein 40,
NL-3015 GD Rotterdam, The Netherlands. E-mail:
e.vandersnoek@erasmusmc.nl
Human papillomavirus (HPV) infection is the most
common sexually transmitted viral infection and has a
steadily increasing prevalence (1). The prevalence of
genital subclinical and latent HPV infection in sexually
active women and men ranges from 10 to 46%, depend-
ing on country and population tested (2).
Anal cancer is an uncommon cancer in men in western
European countries and the USA. The incidence of anal
cancer in the general population is between 7 and 9 per
million and has increased in recent decades (3). Anal
cancer shares many features with cervical cancer,
including a similar histology and a tendency to arise in
the transformation zone, where the columnar epithelium
changes to squamous epithelium (4). HPV DNA has
been identified in 46–100% of all in situ and invasive
squamous cell carcinomas of the anus (3, 5). There is
evidence that the HPV types that are causally linked to
cervical cancer may also be linked to anal cancer. In a
study in Denmark and Sweden, among 388 patients with
invasive or in situ anal carcinomas in women and men,
HPV-16 was detected by PCR in 73% (3). A large
number of partners, young age at the time of first
(receptive anal) sexual contact, unmarried status, a
variety of concomitant (rectal) sexually transmitted
diseases (STDs) and a history of rectal genital warts
are all linked to the risk of anal cancer (3).
Probably, only persistent infections may trigger
carcinogenic development (6). Suppressed cellular
immunity in HIV-positive persons and organ transplant
recipients receiving immunosuppressive therapy is asso-
ciated with persistence of HPV infection in cervical
cancer (7).
The incidence of anal cancer in men who have sex
with men (MSM) was estimated to be at least 44 times
higher than in the general population, while the
incidence of anal cancer among HIV-positive MSM
may be about twice that of HIV-negative MSM (8). In a
population-based study linking HIV and cancer regis-
tries, the risk of anal cancer among persons with HIV
was 84 times greater than in the general population (9,
10). According to Del Mistro & Chieco Bianchi (11),
HIV-infected MSM are at increased risk for persistent
HPV infection.
Goldie et al. (4, 12) stated that screening HIV-
negative MSM for preneoplastic anal lesions with anal
cytology every 2 or 3 years would provide life expectancy
benefits, and would be cost-effective. In HIV-positive
MSM annual screening was found to be cost-effective.
Most HPV infections are transient; about 70% of
infections with HPV are cleared within 1 year and as
many as 91% are cleared within 2 years (13). The mean
duration of high-risk HPV infection is longer than that
of low-risk HPV infection (6). Other data showed that
HPV DNA positivity may be more persistent for high-
risk HPV types 16, 18, 31, 33 and 35 (14).
To develop strategies for prevention and early
treatment of HPV-associated preneoplastic anal lesions
and anal carcinoma, a better understanding of clearance
of HPV infection is needed. Knowledge of the pre-
valence of HPV in anal specimens could be the first step
towards the development of an effective vaccine to
prevent HPV-related anal carcinoma.
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In this study data with regard to HPV prevalence and
HIV serostatus of MSM at two planned cohort visits,
with a median interval of 21 months, were compared.
Data on the first visit were published elsewhere (15). The
major goal was to study clearance and acquisition of
anal HPV infection, and to investigate possible differ-
ences between HIV-positive and HIV-negative cohort
participants.
MATERIALS AND METHODS
Study population and study design
The study was performed at the STD clinic of the Department
of Dermatology and Venereology, Erasmus MC, Rotterdam,
the Netherlands. From February 1999 to February 2000, we
recruited 286 MSM to participate in the Rotterdam cohort
study. MSM were recruited by trained volunteers at gay
meeting places like bars and saunas. Both HIV-positive and
HIV-negative individuals were asked to join the study. The
way participants were recruited has been described in more
detail elsewhere (15). At enrolment, all participants provided
written informed consent. The ethics committee of our medical
centre approved the protocol.
Cohort participants were tested for STD and HIV every 6
months, over a period of 3 years. HPV specimens were only
taken during the third and sixth visit.
Data collection and questionnaires
Demographic and sexual behavioural data were collected.
These included ethnic background, age, educational qualifica-
tion, sexual orientation and number of sexual partners during
the last 6 months. Also, data were collected about age of first
sexual experience, estimated number of lifetime sexual partners
and the presence of genital warts in the past by using self-
administered questionnaires.
Venereological examination
At enrolment and at each semi-annual visit, all participants
underwent a standardized venereological examination as
described previously (16). In brief, the examination included
testing for urethral, rectal and oropharyngeal gonorrhoea and
urethral and rectal Chlamydia trachomatis infection. Blood
samples were taken to be tested for HIV antibodies, syphilis
and hepatitis B. In HIV-positive men blood samples were
taken for a CD4+ lymphocyte count every 3 months.
HPV DNA sample collection
Specimens for assessment of HPV DNA were collected using a
dry swab (Medical Wire & Equipment Co. Ltd, Corsham,
Wiltshire, UK), swabbing the perianal area. The swabs were
immediately placed into standard collecting tubes without
transport medium and sent to the Department of Virology for
further processing.
All third visit specimens were taken between March 2000
and September 2001 and all sixth visit specimens were taken
during the period January 2002 to May 2003.
Detection and typing of HPV DNA
During the third visit HPV DNA testing was carried out in 119
of the 258 men (46.1%) by using a specific HPV type detection
PCR for HPV-6, -11, -16, -18, -31 and -33, as described before
(15, 17) (Fig. 1). Later on, the SPF LiPA (18) HPV PCR-
reverse hybridization test, detecting 25 different HPV types,
i.e. 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53,
54, 56, 58, 59, 66, 68, 70, 74 and ‘unclassified’ (XX), was used
in 139 of 258 men (53.9%).
Van Doorn et al. (19) showed that LiPA results are highly
concordant with those of genotype-specific tests. The total
nucleic acid DNA was extracted by using the total nucleic acid
isolation kit on a MagnaPure LC system (Roche Applied
Science, Penzberg, Germany).
We used the epidemiologic classification according to
Munoz et al. (20), which grouped HPV types 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 as high-risk and
considered types 26, 53 and 66 as probably high-risk. When
high-risk and low-risk HPV types were compared in our study,
HPV types 53 and 66 were considered as high-risk types. HPV
types 26, 73 and 83 were not tested in this study. During the
sixth visit, 213 participants were tested for HPV DNA with the
SPF LiPA HPV PCR-reverse hybridization test (Fig. 1).
As two different HPV detection methods were used, all
individuals tested for HPV types 6–33 are, for analytical
purposes, referred to as group A. Those tested for HPV types
34–74 at both visits are referred to as group B.
Statistics
Data were compared to assess statistically significant differ-
ences in the prevalence of HPV related to HIV status.
Prevalence was calculated as the number of positive tests by
type per 100 tested individuals. Persistent cases of HPV were
defined as cases which were prevalent at both visits. Fisher’s
exact test was used to test differences in prevalence of various
HPV types between HIV-negative and HIV-positive MSM. A
test was considered significant if the p value was v0.05.
Incidence rates of infection with individual HPV types, and
their associated 95% confidence intervals (CI), were calculated
on the basis of the numbers of cases in which a given type was
detected among MSM at the sixth visit who were free of that
type at the third visit. Calculation of the CI was based on the
Poisson distribution (21).
RESULTS
Fig. 1 shows a flow chart of the study material, starting
with a cohort of 286 men at visit 1 and finally with a
cohort of 213 men at visit 6. During the third visit, 258
men still participating in the cohort study (subcohort,
90.2% of the original cohort) were tested for HPV DNA
and during the sixth visit 213 men were tested (82.6% of
the subcohort).The median duration between the third
and sixth visit was 21 months (range 7–32 months).
Population characteristics
During the third visit, 258 men (subcohort) were tested,
including 17 HIV-positive men and 241 HIV-negative
men. During the sixth visit, 213 men were tested (82.6%
of the subcohort), including 17 HIV-positive men and
196 HIV-negative men. None of the MSM refused
perianal testing for HPV DNA.
Forty-five participants (17.4% of the subcohort) were
only tested for HPV at the third visit, as they dropped
out before the sixth visit. These participants were
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comparable to the rest of the subcohort with respect to
sexual orientation (percentage bisexual: 20.0 versus
9.9%; p50.071), median number of sexual partners
during the last 6 months (5 versus 8; p50.090) and
median age at first sexual contact (both groups: 18
years). Those who were not followed up were signifi-
cantly younger (median age 38 versus 43 years;
p50.011), less often had a college degree (28.9 versus
48.0%; p50.021) and more often were of non-Dutch
descent (11.1 versus 3.3%; p50.039).
Of the subcohort tested during the third visit, four
HIV-positive men did not show up and could therefore
not be tested for the second time. Of the 17 HIV-positive
men tested at the sixth visit, four were detected since
their third semi-annual visit and had therefore serocon-
verted recently. The median CD4+ lymphocyte count of
all tested HIV-positive participants at the third visit was
600/mm3 (range 340–1020) compared to 570/mm3 (range
230–1100) at the sixth visit. During the third visit, only
one HIV-positive MSM had a CD4+ lymphocyte count
of (350/mm3 compared with five HIV-positive MSM
tested during the sixth visit. Viral loads were undetect-
able (RNA plasma viraemia below 50 copies/ml) during
the third visit in five MSM. The mean viral load in the
other men was 4.16104 copies/ml. At both visits, 5 of
the 17 HIV-positive individuals were on antiretroviral
therapy.
With regard to demographics, the 17 HIV-positive
MSM at the third visit were comparable to the 241 HIV-
negative MSM of the subcohort with respect to sexual
orientation (percentage bisexual: 0 versus 12.4%;
p50.23), age (median age: 43 versus 42 years; p50.80),
ethnicity (MSM of non-Dutch descent: 5.9 versus 4.6%;
p50.57), educational qualification (college degree: 33.3
versus 45.2%; p50.43), median age at first sexual
contact (median age: 17 versus 18 years, p50.93) and
median number of sexual partners during the last 6
months (median number: 10 versus 6; p50.074).
Of all HIV-positive MSM, 5 (29.4%) had had genital
warts in the past versus 40 HIV-negative MSM (16.6%,
p50.19).
At the third visit perianal warts were found in six
(2.3%) individuals compared to five (2.3%) MSM at the
sixth visit. HPV-6 was detected in three individuals and
HPV-11 in five. Surprisingly, in three of the MSM with
perianal warts no HPV could be detected at the perianal
region.
In this study no data were available about cigarette
smoking. An estimated minority of v5% of the
participants were circumcised.
Fig. 1. Flow chart of the study material. The triangle symbols the number of men and HIV serostatus tested by using a specific HPV type detection
PCR at the third visit. The circles indicates the number of men and HIV serostatus tested by using the SPF LiPA HPV PCR-Reverse Hybridization
test at the third and/or sixth visit.
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HPV findings
Table I summarizes the detection of HPV DNA in
perianal specimens in HIV-positive and HIV-negative
men at the third and sixth visit. Data on HPV positivity at
the third visit have been published elsewhere (15). At the
third visit, 90 of the 258 (34.9%) perianal specimens in
group A were positive for at least one HPV type
compared to 78 of the 213 (36.6%) specimen at the sixth
visit. Types most often detected were HPV-6 and -16
(13.2/12.2% and 10.5/11.7% at visit three and six,
respectively). Of the 139 MSM in group B tested at the
third visit 60 (43.2%) were positive for at least one HPV
type compared to 57/116 MSM (49.1%) at the sixth visit.
Most often detected at the last visit were HPV-51 (12.9%),
HPV-53 (10.3%), HPV-44 (9.5%) and HPV-66 (8.6%).
Table I shows that HPV-16, -18, -31 and -33 were
detected in perianal specimens significantly more often
in HIV-positive participants during both visits in group
A. In group B only HPV-52 was detected significantly
more often in HIV-positive MSM during both visits.
HPV types 39, 44, 51 and 66 were significantly more
often detected in HIV-positive individuals but only
during the sixth visit.
During the visit, two or more different types of HPV
were more often found in perianal specimens of HIV-
positive men than in HIV-negative men, namely 14 times
(82.4%) versus 66 times (33.7%; pv0.0005). High-risk
HPV types at the perianal region were found in 15 HIV-
positive men (88.2%) and in 91 (46.4%) of the HIV-
negative men (p50.001).
Acquisition and clearance
The detection of the 12 most frequently detected HPV
types (those with >7% cumulative positivity) in perianal
specimens at the third visit and the clearance and
acquisition rates per 100 men-months for each HPV
type are summarized in Table II. HPV-51 was the most
frequent incident type (0.52% per month), followed by
HPV-53 and HPV-16 (0.48 versus 0.37% per month).
Clearance was seen most often for HPV-52 (5.15% per
month), followed by HPV-68 (5.00% per month), HPV-39
and HPV-11 (both 4.79% per month).
Table II also classifies HPV types on the basis of the
tendency for a given type to persist during both visits.
The right-hand column in Table II shows the ratio
between the frequency of positivity in both visits and
Table I. Detection of human papillomavirus (HPV) types in perianal specimens in HIV-positive and HIV-negative men (n; %) at










Group Aa 241 17 196 17
HPV-6 30 (12.4) 4 (23.5) n.s. 22 (11.2) 4 (23.5) n.s.
HPV-11 19 (7.9) 1 (5.9) n.s. 9 (4.6) 2 (11.8) n.s.
HPV-16 22 (9.1) 5 (29.4) 0.022 19 (9.7) 6 (35.3) 0.007
HPV-18 9 (3.7) 4 (23.5) 0.006 13 (6.6) 7 (41.2) v0.001
HPV-31 18 (7.5) 4 (23.5) 0.045 4 (2.0) 5 (29.4) v0.001
HPV-33 8 (3.3) 4 (23.5) 0.005 7 (3.6) 3 (17.6) 0.036
Group B 129 10 104 12
HPV-34 0 0 – 2 (1.9) 0 n.s.
HPV-35 5 (3.9) 0 n.s. 3 (2.9) 1 (8.3) n.s.
HPV-39 7 (5.4) 2 (20) n.s. 2 (1.9) 3 (25) 0.008
HPV-40 4 (3.1) 0 n.s. 0 0 –
HPV-42 0 0 – 1 (1.0) 0 n.s.
HPV-43 2 (1.6) 0 n.s. 4 (3.8) 2 (16.7) n.s.
HPV-44 7 (5.4) 1 (10) n.s. 7 (6.7) 4 (33.3) 0.015
HPV-45 5 (3.9) 1 (10) n.s. 3 (2.9) 1 (8.3) n.s.
HPV-51 6 (4.7) 1 (10) n.s. 11 (10.6) 4 (33.3) 0.049
HPV-52 10 (7.8) 6 (60) v0.0005 5 (4.8) 4 (33.3) 0.006
HPV-53 7 (5.4) 1 (10) n.s. 9 (8.7) 3 (25) n.s.
HPV-54 2 (1.6) 0 n.s. 1 (1.0) 0 n.s.
HPV-56 2 (1.6) 0 n.s. 3 (2.9) 1 (8.3) n.s.
HPV-58 0 0 – 0 1 (8.3) n.s.
HPV-59 3 (2.3) 0 n.s. 5 (4.8) 1 (8.3) n.s.
HPV-66 2 (1.6) 0 n.s. 6 (5.8) 4 (33.3) 0.010
HPV-68 10 (7.8) 3 (30) 0.053 5 (4.8) 1 (8.3) n.s.
HPV-70 2 (1.6) 0 n.s. 5 (4.8) 2 (16.7) n.s.
HPV-74 2 (1.6) 0 n.s. 7 (6.7) 0 n.s.
HPV-XX 2 (1.6) 0 n.s. 3 (2.9) 0 n.s.
aGroups A and B are defined in Fig. 1.
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that in one visit, as an indication of the tendency of a
given type to persist. The ratio for all HPV types isv1.
The ratio for HPV-6 was 0.5, indicating that an HPV-6
infection was twice as often detected at only one of the
two test visits.
Relation with HIV serostatus
The tendency to persist of the 12 most frequently
detected perianal HPV types in HIV-positive and HIV-
negative men shows that the tendency of HPV-31 for
being persistent was significantly stronger in HIV-
positive MSM (p50.036).
The incidence of perianal HPV-16 infection could
possibly be associated with HIV positivity (p50.059)
(Table III). Other types did not show a (close to)
significant relation in this table.
DISCUSSION
In this study we examined the persistence and incidence
of perianal HPV infection in a Dutch cohort of MSM,
and showed that HPV infection was relatively frequent:
up to 50% of all MSM tested for HPV infection in group
B at the perianal region were positive for one or more of
the investigated HPV types. Nearly 40% of the HIV-
positive participants tested were positive for HPV-16 or
HPV-18 at the perianal site at both visits. During this visit
two or more different types of HPV were more often
found in perianal specimens of HIV-positive men than in
HIV-negative men. The most common HPV infections at
the perianal site were HPV-6, -16, -18 and -31.
The high-risk HPV-51 was the most frequent incident
type in this study (0.52% per month). The incidence of
perianal HPV-16 infection showed a strong tendency
towards association with HIV positivity. In HIV-positive
MSM the tendency to persist was significantly higher
for HPV type 31 at the perianal region, as compared
with HIV-negative MSM.
We propose that a high incidence and a higher
tendency to persist of high-risk perianal HPV infection
(HPV-31 in this study) may be a reason for more frequent
HPV-related disease in HIV-positive MSM. Our results
are largely in accordance with the study on the prevalence
of cervical HPV infection by Franco et al. (6), in which
they showed that in a group of 1425 low-income women
in a high-risk area for cervical cancer the mean infection
duration was longer for high-risk HPV types.
In the HIV-positive participants a significantly higher
persistence of high risk HPV type 31 was seen but not of
other high-risk types or low-risk HPV types. Richardson
Table II. Frequency of human papillomavirus (HPV) types in perianal specimens in all men at third visit and cumulative positivity at

















HPV-6 29 (13.6) 15 (51.7) 4.46 12 (5.6) 0.30 14 (6.6) 0.5
HPV-11 14 (6.6) 10 (71.4) 4.79 7 (3.3) 0.16 4 (1.9) 0.2
HPV-16 25 (11.7) 15 (60.0) 4.30 15 (7.0) 0.37 10 (4.7) 0.3
HPV-18 10 (4.7) 5 (50.0) 4.55 15 (7.0) 0.34 5 (2.3) 0.3
HPV-31 19 (8.9) 17 (89.5) 4.70 7 (3.3) 0.17 2 (0.9) 0.1
HPV-33 9 (4.2) 5 (55.6) 4.33 6 (2.8) 0.14 4 (1.9) 0.4
Group B (n5116)
HPV-39 8 (6.9) 6 (75.0) 4.79 3 (2.6) 0.13 2 (1.7) 0.2
HPV-44 7 (6.0) 3 (42.9) 4.70 7 (6.6) 0.31 4 (3.4) 0.4
HPV-51 5 (4.3) 2 (40.0) 4.55 12 (10.3) 0.52 3 (2.6) 0.2
HPV-52 12 (10.3) 8 (66.7) 5.15 5 (4.3) 0.23 4 (3.4) 0.3
HPV-53 7 (6.0) 6 (85.7) 4.29 11 (9.5) 0.48 1 (0.9) 0.1
HPV-68 11 (9.5) 10 (90.9) 5.00 5 (4.3) 0.23 11 (9.5) 0.1
*Number of cleared cases prevalent cases at sixth visit per 100 men-months.
{Number of incident cases at sixth visit per 100 men-months.
Table III. Incidence of perianal human papillomavirus (HPV)
infection in both HIV-positive and HIV-negative men who have
sex with men (MSM)
Detected HPV type
MSM rate/1000 person months (95% CI)
HIV-positive HIV-negative
Group A
HPV-6 4.9 (0.1–27.4) 3.0 (1.5–5.3)
HPV-11 0.0 (0.0–11.3) 1.2 (0.4–2.9)
HPV-16 15.2 (3.1–44.5) 2.9 (1.5–5.2)
HPV-18 10.3 (1.2–37.0) 2.7 (1.3–4.8)
HPV-31 9.4 (1.1–33.9) 1.0 (0.3–2.6)
HPV-33 0.0 (0.0–15.7) 1.2 (0.4–2.8)
Group B
HPV-39 8.1 (0.2–45.3) 0.5 (0.1–2.7)
HPV-44 6.5 (0.2–36.4) 1.9 (0.5–4.9)
HPV-51 6.6 (0.2–36.9) 4.7 (2.3–8.7)
HPV-52 11.1 (0.3–61.9) 1.5 (0.3–4.3)
HPV-53 14.2 (1.7–51.2) 3.9 (1.7–7.7)
HPV-68 0.0 (0.0–27.3) 1.9 (0.5–4.9)
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et al. (22) found that HPV type 16 was the most
persistent, followed by HPV-31 and HPV-53 in cervical
specimens of w600 female university students in
Montreal, Canada.
High prevalences of high-risk HPV types, as found in
HIV-positive individuals in this study, may go together
with a high detection rate of abnormal perianal cytology
(23). Anal cancer screening should be promoted,
especially in HIV-positive individuals, to prevent
HPV-related malignancies (4, 12, 24).
It is unlikely that variability in sample collection can
explain the differences in HPV detection. During both
visits, w90% of all perianal HPV specimens were
collected by the same physician. All other men were
examined by the same, thoroughly instructed, research
nurse at both visits.
Given the fact that MSM from the Rotterdam region
were invited to join the cohort, it is most likely that the
cohort participants were not representative of the MSM
population at large in the Netherlands. One of the major
limitations of our study is the relatively small number of
HIV-positive individuals; however, this is in concor-
dance with the modest rate of HIV seropositivity
amongst MSM in the Netherlands (25).
Another important issue in this study is that we
cannot measure true persistence among those positive
for a specific HPV type at enrolment. As yet it is still
impossible to distinguish a new infection with a certain
HPV type from a persistent infection, within the
limitations of the HPV detection method. For this
reason we can only measure the ‘presumed’ persistent
rate of those positive at enrolment. Maybe type-specific
serology will enable discrimination between a new
infection and persistent infection in the future.
Understanding the epidemiology of perianal HPV
infection is important for the prevention of HPV-related
disease in MSM. Longitudinal studies in different
geographic areas may provide information which can
also be used for prevention and future immunization
programmes (26). Further studies in MSM are needed
to establish additional risk factors related to HPV
persistence.
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